Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission

Inflammatory Bowel Diseases

Volumn 15, Issue 5, 2009, Pages 750-755

  Rubin, David T ^a   Surma, Bonnie L ^a   Gavzy, Samuel J ^a   Schnell, Kerry M ^a   Bunnag, Alana P ^a   Huo, Dezheng ^a   Appelbaum, Daniel E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Positron emission tomography; Quiescent inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; FLUORODEOXYGLUCOSE F 18; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE DURATION; DRUG UPTAKE; ENDOSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INFLAMMATION; MALE; PANCOLITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCTOSIGMOIDITIS; RELAPSE; REMISSION; SENSITIVITY ANALYSIS; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 67650323902     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20819     Document Type: Article

References (14)

1. Rubin DT, Kavitt RT. Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:581-604.
2. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030-1038.
3. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623-648; discussion 649-650.
4. Hannah A, Scott AM, Akhurst T, et al. Abnormal colonic accumulation of fluorine-18-FDG in pseudomembranous colitis. J Nucl Med. 1996; 37:1683-1685.
5. Jamieson D, Alavi A, Jolles P, et al. Positron emission tomography in the investigation of central nervous system disorders. Radiol Clin North Am. 1988;26:1075-1088.
6. Lemberg DA, Issenman RM, Cawdron R, et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:733-738.
7. Mernagh JR, Thompson M, Jacobson K, et al. Assessment of inflammation in inflammatory bowel disease with FDG-PET. Radiology. 1998; 209(suppl):172-172.
8. Meisner RS, Spier BJ, Einarsson S, et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:993-1000.
9. Neurath MF, Vehling D, Schunk K, et al. Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol. 2002;97:1978-1985.
10. Skehan SJ, Issenman R, Mernagh J, et al. 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Lancet. 1999;354:836-837.
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
12. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
13. Henriksen M, Jahnsen J, Lygren I, et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol. 2006;41:1037-1043.
14. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19: 61-77.